| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -74,873,032 | -50,302,385 |
| Loss on disposal of fixed assets | -157,519 | -150,673 |
| Depreciation and amortization | 1,386,454 | 891,728 |
| Stock-based compensation | 13,126,439 | 9,129,091 |
| Restricted stock awards granted | 257,461 | 257,461 |
| Changes in lease liabilities | 343,592 | -33,688 |
| Receivables | -10,309,322 | -10,308,980 |
| Prepaid expenses and other current assets | 768,086 | -198,243 |
| Accounts payable and accrued expenses | 3,815,813 | 2,844,166 |
| Net cash used in operating activities | -46,244,518 | -26,555,731 |
| Purchase of marketable securities | 136,392,638 | 78,177,790 |
| Proceeds from sales and maturities of marketable securities | 197,383,098 | 119,207,807 |
| Purchases of property and equipment | 1,239,588 | 1,183,745 |
| Payments for leasehold improvements | 383,539 | 375,008 |
| Payments for construction in progress | 4,976,312 | 1,031,264 |
| Net cash provided by investing activities | 54,391,021 | 38,440,000 |
| Proceeds from exercise of stock awards and warrants | 76,884 | 69,934 |
| Net cash provided by financing activities | 76,884 | 69,934 |
| Net increase in cash and cash equivalents | 8,223,387 | 11,954,203 |
| Cash and cash equivalents at beginning of period | 11,286,996 | - |
| Cash and cash equivalents at end of period | 19,510,383 | - |
CAPRICOR THERAPEUTICS, INC. (CAPR)
CAPRICOR THERAPEUTICS, INC. (CAPR)